Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Akero Therapeutics, Inc. (AKRO) had Weighted-Average Shares Outstanding (Diluted) of 78.66M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-70.72M |
|
-- |
|
-- |
|
$80.88M |
|
$-80.88M |
|
$10.16M |
|
$-70.72M |
|
$-70.72M |
|
$-70.72M |
|
$-70.72M |
|
$-70.72M |
|
$-70.72M |
|
$-80.88M |
|
$-83.17M |
|
78.66M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
78.66M |
$-0.90 |
|
$-0.90 |
|
| Balance Sheet Financials | |
$713.15M |
|
-- |
|
$442.69M |
|
$1.16B |
|
$42.44M |
|
$29.11M |
|
$29.56M |
|
$72.00M |
|
$1.08B |
|
$1.08B |
|
$1.08B |
|
79.67M |
|
| Cash Flow Statement Financials | |
$-67.66M |
|
$-482.18M |
|
$395.53M |
|
$340.24M |
|
$185.92M |
|
$-154.32M |
|
$8.78M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.80 |
|
-- |
|
-- |
|
0.03 |
|
0.03 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-67.66M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.53% |
|
-6.53% |
|
-6.12% |
|
-6.35% |
|
$13.60 |
|
$-0.86 |
|
$-0.86 |
|